X0306 4 2022-02-01 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001829069 Sanna Bastiano C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Cell & Genetic Therapies Common Stock 2022-02-01 4 A 0 11628 0.00 A 44204 D Common Stock 2022-02-01 4 A 0 12314 0.00 A 56518 D Common Stock 2022-02-01 4 F 0 526 243.64 D 55992 D Common Stock 2022-02-02 4 S 0 670 250.04 D 55322 D Common Stock 2022-02-02 4 S 0 141 251.47 D 55181 D Common Stock 2022-02-02 4 S 0 149 253.07 D 55032 D Common Stock 2022-02-02 4 S 0 64 253.95 D 54968 D Common Stock 2022-02-02 4 S 0 16 254.54 D 54952 D Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. Restricted stock unit award that vests in installments beginning on 02/24/2023. Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $250.04 (range $250.00 to $250.97). Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $251.47 (range $251.09 to $251.85). Open market sales reported on this line occurred at a weighted average price of $253.07 (range $252.44 to $253.42). Open market sales reported on this line occurred at a weighted average price of $253.95 (range $253.47 to $254.42). Open market sales reported on this line occurred at a weighted average price of $254.54 (range $254.47 to $254.80). Exhibit 24 - Power of Attorney /s/ Sabrina Yohai, Attorney-in-Fact 2022-02-03